68Ga-labeled DOTA-peptides and 68Ga-labeled radiopharmaceuticals for positron emission tomography: Current status of research, clinical applications, and future Perspectives

Seminars in Nuclear Medicine

Volumn 41, Issue 4, 2011, Pages 314-321

  Breeman, Wouter A P ^a   De Blois, Erik ^a   Sze Chan, Ho ^a   Konijnenberg, Mark ^a   Kwekkeboom, Dik J ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 1 NAL 3 OCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE 8 THREONINE OCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE OCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE OCTREOTIDE Y 86; DIETHYLENETRIAMINEPENTAACETATE OCTREOTIDE IN 111; GALLIUM 68; LUTETIUM 177; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM 90;

DOSIMETRY; DRUG ABSORPTION; DRUG HALF LIFE; DRUG PURIFICATION; HUMAN; ISOTOPE LABELING; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; REVIEW; ROBOTICS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

FORECASTING; GALLIUM RADIOISOTOPES; HUMANS; MOLECULAR STRUCTURE; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVITY; RADIONUCLIDE GENERATORS; RADIOPHARMACEUTICALS; UNITED STATES;

EID: 79957690379     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2011.02.001     Document Type: Review

References (84)

1. Mirzadeh S, Lambrecht RM: Radiochemistry of germanium. Journal of Radioanalytical and Nuclear Chemistry 202:7-102, 1996 (Pubitemid 26056581)
2. Rosenfeld G: Studies of the metabolism of germanium. Arch Biochem Biophys 48:84-94, 1954
3. Roesch F, Riss PJ: The renaissance of the Ge/Ga radionuclide generator initiates new developments in Ga radiopharmaceutical chemistry. Curr Top Med Chem 10:1633-1668, 2010
4. Naidoo C, van der Walt TN: Cyclotron production of 67Ga(III) with a tandem natGe-natZn target. Appl Radiat Isot 54:915-919, 2001 (Pubitemid 32157531)
5. Aardaneh K, van der Walt TN: Ga2O for target, solvent extraction for radiochemical separation and SnO(2) for the preparation of a Ge-68/ Ga-68 generator. Journal of Radioanalytical and Nuclear Chemistry 268:25-32, 2006 (Pubitemid 43372049)
6. Gleason GI: A positron cow. Int J Appl Radiat Isot 8:90-94, 1960
7. Fani M, Andre JP, Maecke HR: 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging 3:67-77, 2008
8. Antunes P, Ginj M, Zhang H, et al: Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34:982-993, 2007
9. Wadas TJ, Wong EH, Weisman GR, et al: Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 110:2858-2902, 2010
10. Baum RP, Prasad V, Müller D, et al: Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med 51:892-897, 2010
11. Hofmann M, Maecke H, Börner R, et al: Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1751-1757, 2001
12. Meyer GJ, Mäcke H, Schuhmacher J, et al: 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 31:1097-1104, 2004
13. Ocak M, Antretter M, Knopp R, et al: Full automation of (68)Ga labelling of DOTA-peptides including cation exchange prepurification. Appl Radiat Isot 68:297-302, 2010
14. Prasad V, Ambrosini V, Hommann M, et al: Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTANOC receptor PET/CT. Eur J Nucl Med Mol Imaging 37:67-77, 2010
15. Prasad V, Baum RP: Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging 54:61-67, 2007
16. Prasad V, Fetscher S, Baum RP: Changing role of somatostatin receptor targeted drugs in NET: nuclear medicine's view. J Pharm Pharm Sci 10:321s-337s, 2007
17. Velikyan I, Sundin A, Eriksson B, et al: In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours: impact of peptide mass. Nucl Med Biol 37:265-275, 2010
18. Maecke HR, Hofmann M, Haberkorn U: (68)Ga-labeled peptides in tumor imaging. J Nucl Med 46(Suppl 1):172S-178S, 2005
19. Maecke HR, Andre JP: 68Ga-PET radiopharmacy: a generator-based alternative to 18F-radiopharmacy. Ernst Schering Res Found Workshop 215-242, 2007
20. Vallabhajosula S, Killeen RP, Osborne JR: Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors. Semin Nucl Med 40:220-241, 2010
21. Bauwens M, Chekol R, Vanbilloen H, et al: Optimal buffer choice of the radiosynthesis of (68)Ga-Dotatoc for clinical application. Nucl Med Commun 31:753-758, 2010
22. Breeman WA, Verbruggen AM: The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine? Eur J Nucl Med Mol Imaging 34:978-981, 2007
23. Verbruggen A, Coenen HH, Deverre JR, et al: Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging 35:2144-2151, 2008
24. Ehrhardt GJ, Welch MJ: A new germanium-68/gallium-68 generator. J Nucl Med 19:925-929, 1978 (Pubitemid 9025474)
25. McElvany KD, Hopkins KT, Welch MJ: Comparison of 68Ge/68Ga generator systems for radiopharmaceutical production. Int J Appl Radiat Isot 35:521-524, 1984 (Pubitemid 14111728)
26. Neirinckx RD, Davis MA: Potential column chromatography generators for ionic Ga-68: I-inorganic substrates. J Nucl Med 20:1075-1079, 1979 (Pubitemid 10222064)
27. Egamediev SK, Khujaev S, Mamatkazina AK: Influence of preliminary treatment of aluminum oxide on the separation of Ge-68-Ga-68 radionuclide chain. Journal of Radioanalytical and Nuclear Chemistry 246: 593-596, 2000
28. Bao B, Song M: A new Ge-68/Ga-68 generator based on CeO2. Journal of Radioanalytical and Nuclear Chemistry 213:233-238, 1996
29. Loc'h, C.; Maziere B, Comar D: A new generator for ionic gallium-68. J Nucl Med 21:171-173, 1980
30. Schuhmacher J, Maier-Borst W: A new 68Ge/68Ga radioisotope generator system for production of 68Ga in dilute HCl. Appl Radiat Isot 31-36, 1981
31. Chakravarty R, Shukla R, Ram S, et al: Nanoceria-PAN composite-based advanced sorbent material: a major step forward in the field of clinical-grade 68Ge/68Ga generator. ACS Appl Mater Interfaces 2:2069-2075, 2010
32. Nakayama M, Haratake M, Ono M, et al: A new Ge-68/Ga-68 generator system using an organic polymer containing N-methylglucamine groups as adsorbent for Ge-68. Appl Radiat Isot 58:9-14, 2003 (Pubitemid 35453940)
33. De Blois E, Sze Chan H, Naidoo C, et al: Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptides. Appl Radiat Isot 69:308-315, 2011
34. Breeman WA, De Jong M, Visser TJ, et al: Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 30:917-920, 2003 (Pubitemid 36734213)
35. Breeman WA, de Jong M, de Blois E, et al: Radiolabelling DOTApeptides with 68Ga. Eur J Nucl Med Mol Imaging 32:478-485, 2005
36. Velikyan I, Beyer GJ, Bergström-Pettermann E, et al: The importance of high specific radioactivity in the performance of 68Ga-labeled peptide. Nucl Med Biol 35:529-536, 2008 (Pubitemid 351853426)
37. Velikyan I, Beyer GJ, Langstrom B: Microwave-supported preparation of (68)Ga bioconjugates with high specific radioactivity. Bioconjug Chem 15:554-560, 2004 (Pubitemid 38657861)
38. Velikyan I, Maecke H, Langstrom B: Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjug Chem 19:569-573, 2008 (Pubitemid 351294931)
39. Pourbaix M, Zhang H, Pourbaix A: Presentation of an atlas of chemical and electrochemical equilibria in the presence of a gaseous phase. High Temp Corros Protect Mater 4(parts 1 and 2, 251-2):143-148, 1997 (Pubitemid 127557948)
40. Decristoforo C, Knopp R, von Guggenberg E, et al: A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun 28:870-875, 2007 (Pubitemid 47494113)
41. Zhernosekov KP, Filosofov DV, Baum RP, et al: Processing of generator-produced 68Ga for medical application. J Nucl Med 48:1741-1748, 2007 (Pubitemid 47572722)
42. Gabriel M, Decristoforo C, Kendler D, et al: 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508-518, 2007 (Pubitemid 47571404)
43. Hartmann H, Zöphel K, Freudenberg R, et al: [Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations]. Nuklearmedizin 48:201-207, 2009
44. ICRP. Limits for intakes of radionuclides by workers, vol 30. ICRP Publication Ann. ICRP 8, 1978
45. Reubi JC, Maecke HR: Peptide-based probes for cancer imaging. J Nucl Med 49:1735-1738, 2008
46. Reubi JC, Waser B, Schaer JC, et al: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836-846, 2001 (Pubitemid 32662546)
47. Krenning EP, Kwekkeboom DJ, Bakker WH, et al: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1] and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731, 1993 (Pubitemid 23284773)
48. Eisenwiener KP, Prata MI, Buschmann I, et al: NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 13: 530-541, 2002 (Pubitemid 34535940)
49. Ferreira CL, Lamsa E, Woods M, et al: Evaluation of bifunctional chelates for the development of gallium-based radiopharmaceuticals. Bioconjug Chem 21:531-536, 2010
50. Boros E, Ferreira CL, Cawthray JF, et al: Acyclic chelate with ideal properties for (68)Ga PET imaging agent elaboration. J Am Chem Soc 132:15726-15733, 2010
51. Heppeler A, André JP, Buschmann I, et al: Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting. Chemistry 14:3026-3034, 2008
52. Antunes P, Ginj M, Walter MA, et al: Influence of different spacers on the biological profile of a DOTA-somatostatin analogue. Bioconjug Chem 18:84-92, 2007 (Pubitemid 46145997)
53. Fischman AJ, Babich JW, Strauss HW: A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 34:2253-2263, 1993 (Pubitemid 24002976)
54. Nayak TK, Brechbiel MW: Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug Chem 20:825-841, 2009
55. Mach JP, Carrel S, Forni M, et al: Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation. N Engl J Med 303:5-10, 1980 (Pubitemid 10073390)
56. Otsuka FL, Welch MJ, Kilbourn MR, et al: Antibody fragments labeled with fluorine-18 and gallium-68: in vivo comparison with indium-111 and iodine-125-labeled fragments. Int J Rad Appl Instrum B 18:813-816, 1991
57. Leung K: 68Ga-DOTA synthetic Her2 specific affibody. Bethesda, MD, Molecular Imaging and Contrast Agent Database (MICAD), National Center for Biotechnolgy Information, 2010
58. Breeman WA, de Jong M, Kwekkeboom DJ, et al: Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28:1421-1429, 2001
59. Breeman WA, Kwekkeboom DJ, Kooij PP, et al: Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 36:623-627, 1995
60. Breeman WA, De Jong M, Bernard BF, et al: Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 83:657-663, 1999
61. Breeman WA, VanHagen MP, Visser-Wisselaar HA, et al: In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. J Nucl Med 37:108-117, 1996
62. Kooij PP, Kwekkeboom DJ, Breeman WAP, et al: The effects of specific activity on tissue distribution of [In-111-DTPA-DPhe1]octreotide in humans. J Nucl Med 35:226P, 1994
63. Breeman WA, Kwekkeboom DJ, de Blois E, et al: Radiolabelled regulatory peptides for imaging and therapy. Anti Cancer Agents Med Chem 7:345-357, 2007 (Pubitemid 46813470)
64. van Essen M, Krenning EP, Kam BL, et al: Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 5:382-393, 2009
65. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 90:220-226, 2009
66. Rösch F, Herzog H, Stolz B, et al: Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1-Tyr3-octreotide ([86Y] SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue. Eur J Nucl Med 26:358-366, 1999 (Pubitemid 29176446)
67. Jonard P, Jamar F, Walrand S, et al: Effect of peptide amount on biodistribution of [86Y]DOTA-DPhe1-Tyr3-octreotide ([86Y] SMT487). J Nucl Med 41:260P, 2000
68. Azhdarinia A, Yang DJ, Chao C, et al: Infrared-based module for the synthesis of 68Ga-labeled radiotracers. Nucl Med Biol 34:121-127, 2007 (Pubitemid 46038154)
69. Gonda I, Swift DL: Losses of gallium in common laboratory ware and ways to minimize them. Eur J Nucl Med 18:511-513, 1991
70. Gebhardt P, Opfermann T, Saluz HP: Computer controlled 68Ga milking and concentration system. Appl Radiat Isot 68:1057-1059, 2010
71. Norenberg JP, Petry NA, Schwarz S: Operation of a radiopharmacy for a clinical trial. Semin Nucl Med 40:347-356, 2010
72. Vallabhajosula S: Molecular Imaging: Radiopharmaceuticals for PET and SPECT (ed 1). Berlin, Springer, 2009
73. Reubi JC, Waser B: Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781-793, 2003 (Pubitemid 36612963)
74. Wild D, Wicki A, Mansi R, et al: Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 51:1059-1067, 2010
75. Wild D, Mäcke HR, Waser B, et al: 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 32:724, 2005 (Pubitemid 40897499)
76. Wild D, Mäcke H, Christ E, et al: Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 359:766-768, 2008
77. Ambrosini V, Campana D, Bodei L, et al: 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 51:669-673, 2010
78. Ginj M, Schmitt JS, Chen J, et al: Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem Biol 13:1081-1090, 2006
79. Virgolini I, Ambrosini V, Bomanji JB, et al: Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37:2004-2010, 2010
80. Froidevaux S, Calame-Christe M, Schuhmacher J, et al: A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 45:116-123, 2004 (Pubitemid 47611617)
81. Shetty D, Jeong JM, Ju CH, et al: Synthesis of novel 68Ga-labeled amino acid derivatives for positron emission tomography of cancer cells. Nucl Med Biol 37:893-902, 2010
82. Petrik M, Haas H, Dobrozemsky G, et al: 68Ga-siderophores for PET imaging of invasive pulmonary aspergillosis: proof of principle. J Nucl Med 51:639-645, 2010
83. Knapp FF Jr, Mirzadeh S: The continuing important role of radionuclide generator systems for nuclear medicine. Eur J Nucl Med 21:1151-1165, 1994
84. Nunn AD: Molecular imaging and personalized medicine: an uncertain future. Cancer Biother Radiopharm 22:722-739, 2007